Latham & Watkins LLP represented Pi-Cardia in the licensing transaction.
Venus Medtech (Hangzhou) Inc., the leading transcatheter heart valve medical device player in China, and Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, has announced a collaboration to bring Pi-Cardia’s Leaflex™ technology to China.
Pi-Cardia’s Leaflex™ catheter performs mechanical scoring of valve calcification, restoring leaflets’ mobility and improving valve hemodynamics.
Latham & Watkins LLP represented Pi-Cardia in the licensing transaction with a corporate team led by New York partner Nathan Ajiashvili (Picture) and Bay Area partner Judith Hasko, with associate Maya Ziv.
Law Firms: Latham & Watkins;